1834612-06-4

1834612-06-4 structure

Name: Lumasiran sodium
Chemical Name: Lumasiran sodium
CAS Number: 1834612-06-4
Molecular Formula:
Molecular Weight:
Catalog: Research Areas Metabolic Disease
Create Date: 2022-01-13 07:18:18
Modify Date: 2024-01-06 06:13:35
Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) [1][2].

Name	Lumasiran sodium

Description	Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) [1][2].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Metabolic Disease
In Vitro	Lumasiran sodium can be used for the research of PH1. By silencing the gene encoding glycolate oxidase, Lumasiran sodium depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of PH1[1].
In Vivo	Lumasiran sodium is a subcutaneously administered, liver-directed RNA interference (RNAi) therapeutic agent[2].
References	[1]. Scott LJ, et al. Lumasiran: First Approval. Drugs. 2021;81(2):277-282. [2]. Garrelfs SF, et al. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. N Engl J Med. 2021 Apr 1;384(13):1216-1226.

No Any Chemical & Physical Properties